Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Change in Accured Expenses (2018 - 2025)

Neurogene (NGNE) has disclosed Change in Accured Expenses for 5 consecutive years, with $365000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Accured Expenses fell 86.18% year-over-year to $365000.0, compared with a TTM value of -$409000.0 through Sep 2025, up 64.5%, and an annual FY2024 reading of -$2.8 million, up 22.41% over the prior year.
  • Change in Accured Expenses was $365000.0 for Q3 2025 at Neurogene, down from $2.2 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $2.6 million in Q3 2024 and bottomed at -$4.9 million in Q1 2024.